Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate.
about
EMT-Inducing Molecular Factors in Gynecological CancersRegulation of ovarian cancer stem cells or tumor-initiating cellsABC transporters in CSCs membranes as a novel target for treating tumor relapse.Expression of mitochondrial regulators PGC1α and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinomaDownregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcomeA comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line modelsA multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotypeTargeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burdenValproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.Metabolic enzymes: key modulators of functionality in cancer stem-like cells.The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression.miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.Metabolic profiling of epithelial ovarian cancer cell lines: evaluation of harvesting protocols for profiling using NMR spectroscopy.Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLCEpithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview.Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.PGC1α: Friend or Foe in Cancer?Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance.
P2860
Q26781912-A67ED9FB-ECDF-485A-8C52-DDE4BD826223Q26853096-C3E9D1A4-D119-49C1-BCC5-88697C53F63EQ33879326-3512946B-F280-4248-B88A-D0AD1044B5D2Q34223682-17637961-4C7A-4CF9-8311-5AA9C4098CCAQ36246404-B891AB8D-AAE3-4E9C-AE57-C4EBD1FC994FQ36413261-231575E7-4423-4707-944B-81BC9AF5098BQ36545528-22A4FE68-17BD-446E-9BDB-CAC0D97035AAQ36687966-2C14D97B-9DFB-4956-89B6-22A20D9A2235Q36891437-AA76F168-C0E3-415D-BB28-B85B43177355Q37337989-825DAE52-63EC-4562-B507-4E5440542F48Q37706766-1926106C-02D1-4BD1-8877-DB9A60679EB0Q38556814-76CBD2A1-9221-4826-85BA-15EFF3A693DBQ38705370-58A9FD8E-93F9-47CF-9349-B616A87AC830Q38837920-E2BCC990-F04E-4072-8335-AFD3AE80452AQ38920122-B0B3A0E9-AA77-467B-B7A2-13726A0ED30DQ39042043-5F8CE56B-6F17-47C3-90A7-1C79205A3A71Q42700773-0D975D10-92D7-41C1-97F7-58F5EFDCC3A0Q47260956-A98F00F3-6B8C-4A8F-8233-045D22D63E93Q47371762-6A38229C-354D-4BD0-88BA-1F008D01A5A4Q47844268-5ED50815-7887-472E-BD8E-C52D145F3A1AQ48124146-1768161E-7D88-44FB-8BEB-7F6A9B236143Q53697399-D3451E5C-077A-4793-99C2-FFF54EC7A2B2
P2860
Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Repeated cisplatin treatment c ...... ensitivity to 3-bromopyruvate.
@en
Repeated cisplatin treatment c ...... ensitivity to 3-bromopyruvate.
@nl
type
label
Repeated cisplatin treatment c ...... ensitivity to 3-bromopyruvate.
@en
Repeated cisplatin treatment c ...... ensitivity to 3-bromopyruvate.
@nl
prefLabel
Repeated cisplatin treatment c ...... ensitivity to 3-bromopyruvate.
@en
Repeated cisplatin treatment c ...... ensitivity to 3-bromopyruvate.
@nl
P2093
P2860
P356
P1476
Repeated cisplatin treatment c ...... sensitivity to 3-bromopyruvate
@en
P2093
Anne B Pedersen
Joel Johansson
Lina Löfstedt
Maria Shoshan
My Wintzell
P2860
P304
P356
10.4161/CBT.22007
P50
P577
2012-09-06T00:00:00Z